Literature DB >> 20360940

The extracellular matrix glycoprotein elastin microfibril interface located protein 2: a dual role in the tumor microenvironment.

Maurizio Mongiat1, Stefano Marastoni, Giovanni Ligresti, Erica Lorenzon, Monica Schiappacassi, Roberto Perris, Sergio Frustaci, Alfonso Colombatti.   

Abstract

We have recently reported that elastin microfibril interface located protein 2 (EMILIN2), an extracellular matrix (ECM) glycoprotein, triggers cell death through a direct binding to death receptors. EMILIN2 thus influences cell viability through a mechanism that is unique for an ECM molecule. In the present work, we report an additional function for this molecule. First, we identify the region responsible for the proapoptotic effects, a 90-amino acid residue-long coiled-coil fragment toward the N-terminus of the molecule. The fragment recapitulates EMILIN2 proapoptotic mechanisms. In addition, using either the full molecule or the active fragment, for the first time, we demonstrate a significant antitumoral effect in vivo, likely due to a decrease in tumor cell viability. Unexpectedly, tumors treated with EMILIN2 or the deletion mutant display a significant increase of tumor angiogenesis. In view of this novel finding, the cotreatment of the growing tumors with an antiangiogenic drug led, in most cases, to a complete regression of tumor growth. These results grant further support to recent findings that pinpoint the microenvironment as an important regulator of cell fate under both physiological and pathological conditions and disclose the possibility of using EMILIN2 fragments as potent antineoplastic tools for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20360940      PMCID: PMC2847737          DOI: 10.1593/neo.91930

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  50 in total

1.  Regulation of the extrinsic apoptotic pathway by the extracellular matrix glycoprotein EMILIN2.

Authors:  Maurizio Mongiat; Giovanni Ligresti; Stefano Marastoni; Erica Lorenzon; Roberto Doliana; Alfonso Colombatti
Journal:  Mol Cell Biol       Date:  2007-08-13       Impact factor: 4.272

Review 2.  Extracellular matrix: a matter of life and death.

Authors:  Stefano Marastoni; G Ligresti; E Lorenzon; Alfonso Colombatti; Maurizio Mongiat
Journal:  Connect Tissue Res       Date:  2008       Impact factor: 3.417

Review 3.  The TRAIL apoptotic pathway in cancer onset, progression and therapy.

Authors:  Ricky W Johnstone; Ailsa J Frew; Mark J Smyth
Journal:  Nat Rev Cancer       Date:  2008-10       Impact factor: 60.716

4.  TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5.

Authors:  Ching-Huang Wu; Ching-Hai Kao; Ahmad R Safa
Journal:  Hum Gene Ther       Date:  2008-07       Impact factor: 5.695

5.  Emilin1 deficiency causes structural and functional defects of lymphatic vasculature.

Authors:  Carla Danussi; Paola Spessotto; Alessandra Petrucco; Bruna Wassermann; Patrizia Sabatelli; Monica Montesi; Roberto Doliana; Giorgio M Bressan; Alfonso Colombatti
Journal:  Mol Cell Biol       Date:  2008-04-14       Impact factor: 4.272

Review 6.  Targeting the extrinsic apoptosis pathway in cancer.

Authors:  Avi Ashkenazi
Journal:  Cytokine Growth Factor Rev       Date:  2008-05-20       Impact factor: 7.638

Review 7.  VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.

Authors:  Richard J Epstein
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

Review 8.  Bevacizumab in the treatment of breast cancer.

Authors:  Bhawna Sirohi; Katy Smith
Journal:  Expert Rev Anticancer Ther       Date:  2008-10       Impact factor: 4.512

9.  The solution structure of EMILIN1 globular C1q domain reveals a disordered insertion necessary for interaction with the alpha4beta1 integrin.

Authors:  Giuliana Verdone; Roberto Doliana; Alessandra Corazza; Simon A Colebrooke; Paola Spessotto; Simonetta Bot; Francesco Bucciotti; Alessandra Capuano; Alessandra Silvestri; Paolo Viglino; Iain D Campbell; Alfonso Colombatti; Gennaro Esposito
Journal:  J Biol Chem       Date:  2008-05-07       Impact factor: 5.157

Review 10.  Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).

Authors:  Avi Ashkenazi; Pamela Holland; S Gail Eckhardt
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

View more
  21 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Stromal miR-320 keeps an oncogenic secretome in check.

Authors:  Yeesim Khew-Goodall; Gregory J Goodall
Journal:  Nat Cell Biol       Date:  2012-02-02       Impact factor: 28.824

Review 3.  MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment.

Authors:  F J Kohlhapp; A K Mitra; E Lengyel; M E Peter
Journal:  Oncogene       Date:  2015-04-13       Impact factor: 9.867

4.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

5.  Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers.

Authors:  Mathewos Tessema; Christin M Yingling; Yushi Liu; Carmen S Tellez; Leander Van Neste; Stephen S Baylin; Steven A Belinsky
Journal:  Carcinogenesis       Date:  2014-01-07       Impact factor: 4.944

6.  UEG Week 2020 Poster Presentations.

Authors: 
Journal:  United European Gastroenterol J       Date:  2020-10       Impact factor: 4.623

7.  The ablation of the matricellular protein EMILIN2 causes defective vascularization due to impaired EGFR-dependent IL-8 production affecting tumor growth.

Authors:  Alice Paulitti; Eva Andreuzzi; Dario Bizzotto; Rosanna Pellicani; Giulia Tarticchio; Stefano Marastoni; Chiara Pastrello; Igor Jurisica; Giovanni Ligresti; Francesco Bucciotti; Roberto Doliana; Roberta Colladel; Paola Braghetta; Evelina Poletto; Alessia Di Silvestre; Giorgio Bressan; Alfonso Colombatti; Paolo Bonaldo; Maurizio Mongiat
Journal:  Oncogene       Date:  2018-02-27       Impact factor: 9.867

8.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

Review 9.  Extracellular Matrix: Emerging Roles and Potential Therapeutic Targets for Breast Cancer.

Authors:  Yunchun Zhao; Xiaoling Zheng; Yongquan Zheng; Yue Chen; Weidong Fei; Fengmei Wang; Caihong Zheng
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

10.  Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320.

Authors:  A Bronisz; J Godlewski; J A Wallace; A S Merchant; M O Nowicki; H Mathsyaraja; R Srinivasan; A J Trimboli; C K Martin; F Li; L Yu; S A Fernandez; T Pécot; T J Rosol; S Cory; M Hallett; M Park; M G Piper; C B Marsh; L D Yee; R E Jimenez; G Nuovo; S E Lawler; E A Chiocca; G Leone; M C Ostrowski
Journal:  Nat Cell Biol       Date:  2011-12-18       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.